Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium ( 186 Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median o
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
07:30am, Thursday, 08'th Aug 2024
AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advan
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
07:30am, Thursday, 25'th Jul 2024
AUSTIN, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutic
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
07:30am, Tuesday, 02'nd Jul 2024
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutic
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
07:30am, Friday, 07'th Jun 2024
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Med
Plus Therapeutics Announces New Employment Inducement Grants
05:00pm, Friday, 17'th May 2024
AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanc
Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Call Transcript
09:18pm, Wednesday, 15'th May 2024
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q1 2024 Earnings Conference Call May 15, 2024 5:00 PM ET Company Participants Marc Hedrick - President and Chief Executive Officer Andrew Sims - Vice President a
Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
04:15pm, Wednesday, 15'th May 2024
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program Acquired
Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024
07:30am, Monday, 13'th May 2024
AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanc
Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, “CNSide™ ” and discussed potential partnering opportunities CNSide can significantly improve LM di
Company acquired all assets for the synergistic CNSide cerebrospinal fluid diagnostic portfolio Company will summarize topline data from the FORESEE clinical trial planned for presentation at the SNO/
Plus Therapeutics Announces Private Placement Financing of up to $18 Million
07:30am, Monday, 06'th May 2024
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanc
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
07:00am, Monday, 22'nd Apr 2024
Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline Funding for pediatric brain cancer treatment is expected to begin in Q3 2024, pending contract
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.
07:00am, Tuesday, 09'th Apr 2024
The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient
Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript
07:07pm, Tuesday, 05'th Mar 2024
Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2023 Earnings Conference Call March 5, 2024 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Norman LaFrance - CMO Conferenc
